People · Operator
Named in public records as an officer, director or promoter · active 2009–2012 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Combinent BioMedical Systems, Inc. | — | Pharmaceuticals | Seed | $3.4M | $22.8M | 2009 |
| Neotropix Inc | — | Pharmaceuticals | Seed | $1.4M | $53.3M | 2009 |
Peter Lanciano at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Lanciano on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sena K. Biswas | 2 | 2 |
| Matthew Rieke | 1 | 3 |
| CHRIS KROEGER | 1 | 2 |
| Rohan K. Hastie | 1 | 1 |
| Carl K. Berke | 1 | 1 |
| Tom K. Umbel | 1 | 1 |
| Joel K. Sussman | 1 | 1 |
| Dennis L. Panicali | 1 | 1 |
| Robert K. Langer | 1 | 1 |
| John K. Ledoux | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.